103 related articles for article (PubMed ID: 20111071)
1. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
2. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Weichsel R; Dix C; Wooldridge L; Clement M; Fenton-May A; Sewell AK; Zezula J; Greiner E; Gostick E; Price DA; Einsele H; Seggewiss R
Clin Cancer Res; 2008 Apr; 14(8):2484-91. PubMed ID: 18413841
[TBL] [Abstract][Full Text] [Related]
3. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Pan C; Olsen JV; Daub H; Mann M
Mol Cell Proteomics; 2009 Dec; 8(12):2796-808. PubMed ID: 19651622
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.
Zhou KI; Lin C; Neff JL; Galal A
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37197831
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.
Tiwari RK; Brown A; Sadeghiani N; Shirazi AN; Bolton J; Tse A; Verkhivker G; Parang K; Sun G
ChemMedChem; 2017 Jan; 12(1):86-99. PubMed ID: 27875633
[TBL] [Abstract][Full Text] [Related]
6. Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas.
Uckun FM; Qazi S
Cancer Drug Resist; 2018; 1():30-47. PubMed ID: 31788667
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib-induced hypoglycemia in a patient with acute lymphoblastic leukemia.
Lundholm MD; Charnogursky GA
Clin Case Rep; 2020 Jul; 8(7):1238-1240. PubMed ID: 32695366
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
Weisberg E; Azab AK; Manley PW; Kung AL; Christie AL; Bronson R; Ghobrial IM; Griffin JD
Leukemia; 2012 May; 26(5):985-90. PubMed ID: 22182920
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
Maletzke S; Salimi A; Vieri M; Schroeder KM; Schemionek M; Masouleh BK; Brümmendorf TH; Koschmieder S; Appelmann I
PLoS One; 2022; 17(10):e0268352. PubMed ID: 36194587
[TBL] [Abstract][Full Text] [Related]
10. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.
Porazzi P; De Dominici M; Salvino J; Calabretta B
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335
[TBL] [Abstract][Full Text] [Related]
11. Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms.
Park NS; Park YK; Yadav AK; Shin YM; Bishop-Bailey D; Choi JS; Park JW; Jang BC
J Cell Mol Med; 2021 Sep; 25(17):8300-8311. PubMed ID: 34318593
[TBL] [Abstract][Full Text] [Related]
12. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment.
Kaczmarska A; Śliwa P; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203891
[TBL] [Abstract][Full Text] [Related]
13. Role of CXCR4 in the progression and therapy of acute leukaemia.
Su L; Hu Z; Yang YG
Cell Prolif; 2021 Jul; 54(7):e13076. PubMed ID: 34050566
[TBL] [Abstract][Full Text] [Related]
14. Leukaemia: a model metastatic disease.
Whiteley AE; Price TT; Cantelli G; Sipkins DA
Nat Rev Cancer; 2021 Jul; 21(7):461-475. PubMed ID: 33953370
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias.
Varallo-Rodriguez C; Freyer CW; Ontiveros EP; Griffiths EA; Wang ES; Wetzler M
Expert Opin Orphan Drugs; 2015; 3(5):599-608. PubMed ID: 31388478
[TBL] [Abstract][Full Text] [Related]
16. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.
Geldenhuys WJ; Nair RR; Piktel D; Martin KH; Gibson LF
J Pharmacol Exp Ther; 2019 Jul; 370(1):25-34. PubMed ID: 31010844
[TBL] [Abstract][Full Text] [Related]
17. Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.
Paz H; Joo EJ; Chou CH; Fei F; Mayo KH; Abdel-Azim H; Ghazarian H; Groffen J; Heisterkamp N
J Exp Clin Cancer Res; 2018 Mar; 37(1):67. PubMed ID: 29580262
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Moehler M; Gepfner-Tuma I; Maderer A; Thuss-Patience PC; Ruessel J; Hegewisch-Becker S; Wilke H; Al-Batran SE; Rafiyan MR; Weißinger F; Schmoll HJ; Kullmann F; von Weikersthal LF; Siveke JT; Weusmann J; Kanzler S; Schimanski CC; Otte M; Schollenberger L; Koenig J; Galle PR
BMC Cancer; 2016 Aug; 16(1):699. PubMed ID: 27582078
[TBL] [Abstract][Full Text] [Related]
19. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
[TBL] [Abstract][Full Text] [Related]
20. Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.
George AA; Paz H; Fei F; Kirzner J; Kim YM; Heisterkamp N; Abdel-Azim H
PLoS One; 2015; 10(9):e0137917. PubMed ID: 26360058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
